Ultragenyx Pharmaceutical Inc. (LON:0LIF)
London · Delayed Price · Currency is GBP · Price in USD 28.31
+1.23 (4.53%)
At close: Aug 7, 2025
CTI BioPharma Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2016 - 2020 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2016 - 2020 |
| 610.16 | 560.23 | 434.25 | 363.33 | 351.41 | 271.03 | Upgrade | |
Revenue Growth (YoY) | 26.77% | 29.01% | 19.52% | 3.39% | 29.66% | 161.32% | Upgrade |
Cost of Revenue | 777.96 | 774.59 | 693.66 | 734.11 | 513.16 | 418.21 | Upgrade |
Gross Profit | -167.8 | -214.36 | -259.41 | -370.78 | -161.76 | -147.18 | Upgrade |
Selling, General & Admin | 337.29 | 321.61 | 309.8 | 278.14 | 219.98 | 182.93 | Upgrade |
Operating Expenses | 337.29 | 321.61 | 309.8 | 278.14 | 219.98 | 182.93 | Upgrade |
Operating Income | -505.09 | -535.97 | -569.21 | -648.92 | -381.74 | -330.12 | Upgrade |
Interest Expense | -59.62 | -63.04 | -66 | -43.02 | -29.42 | -33.29 | Upgrade |
Interest & Investment Income | 36.51 | 36.51 | 26.69 | 11.07 | 1.93 | 7.04 | Upgrade |
Other Non Operating Income (Expenses) | -1.15 | -3.96 | -0.34 | -1.57 | -1.69 | 0.61 | Upgrade |
EBT Excluding Unusual Items | -529.36 | -566.47 | -608.86 | -682.43 | -410.92 | -355.76 | Upgrade |
Gain (Loss) on Sale of Investments | -1.04 | -1.12 | 0.4 | -19.3 | -42.06 | 170.4 | Upgrade |
Pretax Income | -530.39 | -567.59 | -608.46 | -701.73 | -452.98 | -185.36 | Upgrade |
Income Tax Expense | 2.54 | 1.6 | -1.83 | 5.7 | 1.04 | 1.21 | Upgrade |
Net Income | -532.93 | -569.18 | -606.64 | -707.42 | -454.03 | -186.57 | Upgrade |
Net Income to Common | -532.93 | -569.18 | -606.64 | -707.42 | -454.03 | -186.57 | Upgrade |
Shares Outstanding (Basic) | 97 | 91 | 74 | 70 | 68 | 61 | Upgrade |
Shares Outstanding (Diluted) | 97 | 91 | 74 | 70 | 68 | 61 | Upgrade |
Shares Change (YoY) | 19.24% | 23.11% | 5.19% | 3.13% | 11.42% | 7.54% | Upgrade |
EPS (Basic) | -5.52 | -6.29 | -8.25 | -10.12 | -6.70 | -3.07 | Upgrade |
EPS (Diluted) | -5.52 | -6.29 | -8.25 | -10.12 | -6.70 | -3.07 | Upgrade |
Free Cash Flow | - | -421.68 | -519.07 | -496.59 | -411.79 | -176.13 | Upgrade |
Free Cash Flow Per Share | - | -4.66 | -7.06 | -7.10 | -6.07 | -2.90 | Upgrade |
Gross Margin | -27.50% | -38.26% | -59.74% | -102.05% | -46.03% | -54.31% | Upgrade |
Operating Margin | -82.78% | -95.67% | -131.08% | -178.60% | -108.63% | -121.80% | Upgrade |
Profit Margin | -87.34% | -101.60% | -139.70% | -194.70% | -129.20% | -68.84% | Upgrade |
Free Cash Flow Margin | - | -75.27% | -119.53% | -136.68% | -117.18% | -64.98% | Upgrade |
EBITDA | -469.28 | -500.43 | -543.2 | -630.7 | -368.5 | -317.86 | Upgrade |
EBITDA Margin | -76.91% | -89.33% | -125.09% | -173.59% | -104.86% | -117.28% | Upgrade |
D&A For EBITDA | 35.82 | 35.54 | 26.01 | 18.22 | 13.24 | 12.26 | Upgrade |
EBIT | -505.09 | -535.97 | -569.21 | -648.92 | -381.74 | -330.12 | Upgrade |
EBIT Margin | -82.78% | -95.67% | -131.08% | -178.60% | -108.63% | -121.80% | Upgrade |
Revenue as Reported | 610.16 | 560.23 | 434.25 | 363.33 | 351.41 | 271.03 | Upgrade |
Updated Feb 19, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.